A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate

Completed · Phase 2 · Has a placebo group

Conditions studied: Arthritis, Rheumatoid

In brief

The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.

Key facts

Study ID

NCT00620685

Run by

Pfizer

People needed

27

Starts

2008-03-01

Expected to finish

2008-10-01

Last updated by the study team

2018-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult with RA for at least 6 months
• Stable weekly dosage of oral methotrexate 12.5- 25 mg/week

You may not qualify if…

• Severe, progressive and/or uncontrolled other disease
• Chronic or recent serious infection; current infection
• Concomitant use of RA therapy other than methotrexate with some exceptions

Where it is running

• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Colorado Springs, Colorado, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Frederick, Maryland, United States
• Pfizer Investigational Site — Bingham Farms, Michigan, United States
• Pfizer Investigational Site — Kalamazoo, Michigan, United States
• Pfizer Investigational Site — Duncansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.